Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Asset Writedowns and Impairment (2018 - 2025)

Historic Asset Writedowns and Impairment for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to $49.7 million.

  • Takeda Pharmaceutical's Asset Writedowns and Impairment rose 24934.76% to $49.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 20687.41%. This contributed to the annual value of $699.3 million for FY2025, which is 3277.04% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Asset Writedowns and Impairment stood at $49.7 million for Q4 2025, which was up 24934.76% from $575.4 million recorded in Q3 2025.
  • Takeda Pharmaceutical's Asset Writedowns and Impairment's 5-year high stood at $823.1 million during Q3 2023, with a 5-year trough of $484156.0 in Q2 2021.
  • For the 5-year period, Takeda Pharmaceutical's Asset Writedowns and Impairment averaged around $173.6 million, with its median value being $108.1 million (2022).
  • As far as peak fluctuations go, Takeda Pharmaceutical's Asset Writedowns and Impairment crashed by 9930.18% in 2021, and later soared by 2263930.36% in 2022.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Asset Writedowns and Impairment stood at $115.9 million in 2021, then crashed by 63.25% to $42.6 million in 2022, then grew by 20.33% to $51.3 million in 2023, then crashed by 72.26% to $14.2 million in 2024, then skyrocketed by 249.35% to $49.7 million in 2025.
  • Its Asset Writedowns and Impairment stands at $49.7 million for Q4 2025, versus $575.4 million for Q3 2025 and $16.3 million for Q2 2025.